Ferring Pharmaceuticals, which sells hormones used in in vitro fertilisation (IVF), has agreed to acquire Gameto, a biotechnology company developing technology that could substantially reduce the need for those injections.
The proposed acquisition is worth up to $1.38 billion, including payments dependent on development, regulatory and commercial milestones. The upfront payment has not been disclosed, and the acquisition has not yet closed.
Gameto’s lead treatment, Fertilo, is designed to help eggs mature outside the body using engineered ovarian support cells. The aim is to shorten hormonal stimulation before egg retrieval from roughly two weeks to between one and three days. Fertilo remains investigational in the US.
It takes hours each week to research, write, and produce at this level. Consider becoming a free or paid subscriber to support my work. Thank you.
Why the Gameto acquisition matters for women’s health investing
Here’s why I am paying attention to this.
IVF is an established treatment, but the experience still asks a great deal of women. Gameto is working on a specific part of that burden. Its commercial opportunity rests on whether better science can make treatment easier while delivering the outcomes patients and clinicians need.
That connection between an unresolved patient problem and a commercial opportunity is central to our investment thesis at Calabar Capital. I truly believe that an existing market can still contain substantial room for innovation.
The identity of the buyer matters too. Ferring already has a fertility business. My read of this deal is that it sees enough potential in a different treatment approach to bring it into its own portfolio. For a young biotechnology company, an established pharmaceutical business can also provide the expertise and reach needed to move an innovation towards wider use.
For investors, the proposed acquisition adds a concrete example of how a reproductive-health company could eventually find a buyer. These transactions matter because backing promising science is only part of investing: there also needs to be a clear exit strategy.
What the $1.38 billion headline does and does not tell us
Still, the headline figure needs care. We do not know how much will be paid upfront or how much of the maximum consideration will ultimately be earned. It is too early to describe this as $1.38 billion returned to shareholders.
There are clinical questions ahead as well. Fertilo’s Phase 3 trial compares it with standard laboratory egg-maturation medium, rather than directly testing whether it matches conventional, fully stimulated IVF. Its eventual place in fertility care will depend on the evidence.
My view is that this is an encouraging, specific signal for the sector. A major fertility business is pursuing technology aimed at improving a difficult part of women’s treatment. The next things to watch are the clinical results, regulatory progress and whether clinics can translate that promise into a better experience for patients.
My new book, The Billion Dollar Blindspot is now available on Amazon and in bookstores.
About Maryann Selfe
Maryann Selfe is an institutional investor and the Founder and Chief Investment Officer of Calabar Capital, an investment platform backing exceptional managers and founders in women’s health. She is the author of The Billion Dollar Blindspot and writes about women’s-health investing and capital allocation.
Connect on LinkedIn · Discover the Book · Learn more about Calabar Capital
The Billion Dollar Blindspot is an independent publication. Its content is provided for informational and educational purposes only and does not constitute financial advice, an investment recommendation or an offer to buy or sell any security.